KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Deferred Revenue: 2009-2017

Historic Current Deferred Revenue for Acadia Pharmaceuticals (ACAD) over the last 7 years, with Mar 2017 value amounting to $4.1 million.

  • Acadia Pharmaceuticals' Current Deferred Revenue was N/A to $4.1 million in Q1 2017 from the same period last year, while for Mar 2017 it was $4.1 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2016, which is N/A change from last year.
  • According to the latest figures from Q1 2017, Acadia Pharmaceuticals' Current Deferred Revenue is $4.1 million, which was up 56.28% from $2.6 million recorded in Q4 2016.
  • Acadia Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $4.1 million during Q1 2017, with a 5-year trough of $15,000 in Q3 2014.
  • Over the past 2 years, Acadia Pharmaceuticals' median Current Deferred Revenue value was $2.3 million (recorded in 2016), while the average stood at $2.3 million.
  • Data for Acadia Pharmaceuticals' Current Deferred Revenue shows a maximum YoY crashed of 87.33% (in 2013) over the last 5 years.
  • Acadia Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $55,000 in 2013, then tumbled by 81.25% to $15,000 in 2014, then reached $2.6 million in 2016, then reached $4.1 million in 2017.
  • Its Current Deferred Revenue stands at $4.1 million for Q1 2017, versus $2.6 million for Q4 2016 and $1.9 million for Q3 2016.